M. Lazarov

发表

Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model.

R. Buelow, S. Iyer, T. Fong, 2005, The Journal of investigative dermatology.

Escaping G1 Restraints on Neoplasia: Cdk4 Regulation by Ras and NF-KappaB

Jennifer Y. Zhang, P. Khavari, Y. Kubo, 2003, Cell cycle.

RDP58, a novel anti-inflammatory peptide, inhibits multiple intracellular messenger pathways and transcription factors to block TNF-α, IFN-γ, and IL12 production

L. Mo, A. Welihinda, R. Buelow, 2003 .

NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia

Jennifer Y. Zhang, P. Khavari, Y. Kubo, 2003, Nature.

Periodontal regeneration using an anabolic peptide with two carriers in baboons.

B. Mealey, D. Cochran, J. Mellonig, 2010, Journal of periodontology.

NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia.

Jennifer Y. Zhang, P. Khavari, Y. Kubo, 2003, Nature.

CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis

P. Khavari, Y. Kubo, T. Cai, 2002, Nature Medicine.

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

I. Wistuba, J. Zha, L. Rangell, 2014, Clinical Cancer Research.

Absence of HTLV-Related Sequences in Skin Lesions and Peripheral Blood of Cutaneous T-Cell Lymphomas

E. Zandi, A. Smahi, G. Courtois, 2009 .

Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis

C. Hawkey, B. Warren, S. Travis, 2005, Inflammatory bowel diseases.

Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

A. Zelenetz, I. Flinn, B. Coiffier, 2014 .

SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.

C. Rudin, Melissa L. Johnson, D. Brickman, 2020, Lung cancer.

Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC).

L. Amler, R. Yauch, A. Pandita, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

A. Zelenetz, J. Leonard, I. Flinn, 2013 .

Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial

A. Zelenetz, I. Flinn, B. Coiffier, 2014 .